Niagen Bioscience Reports Third Quarter 2026 Financial Results and Expansion of NAD+ Consumer Portfolio

Niagen Bioscience reported $27.2 million in Q3 2026 net sales and launched new consumer NAD+ products, while initiating trial planning with Mass General Brigham and strategic advisory support for its investigational drug candidate NB4168.

Niagen Bioscience reported total net sales of $27.2 million for the third quarter of 2026, which includes $23.3 million from its Tru Niagen product line.

The company recorded a net loss of $1.2 million, resulting in a basic and diluted loss per share of $(0.01), and a positive adjusted EBITDA of $0.5 million.

Operating cash flow reached $2.6 million for the quarter, and cash and cash equivalents increased to $69.5 million as of September 30, 2026, compared to $66.7 million as of June 30, 2026.

Strategic business developments included launching the liquid Niagen At-Home Injection Kit via telehealth and Niagen NanoCloud under a new skincare category.

The company signed a Start-Up Agreement with Mass General Brigham to plan a comprehensive clinical trial of Niagen, and engaged life sciences advisory firm Red Sky Partners to support its therapeutic candidate, NB4168.

The launches of injectable and topical formulations represent a strategic pivot to address competitive market dynamics in the core ingredient business by entering high-margin telehealth and clinical skincare channels.

Initiating structured trial planning with Mass General Brigham indicates an effort to build institutional scientific validation, reinforcing the product's clinical positioning against unregulated NAD+ precursors.

A published analysis in Aging Cell showing Niagen supplementation is associated with reduced muscle epigenetic age acceleration provides clinical literature to back the company's muscle-aging marketing claims.

The shift of NAD+ precursors into telehealth-facilitated injections and dermatologist-tested topicals demonstrates a broader trend of dietary supplement companies moving upstream into structured clinical wellness offerings.

The persistent headwinds in the ingredient supply business underline the growing competitive pressure and price sensitivity within the global wholesale NAD+ precursor sector.

The finalization of the clinical trial protocol under the Mass General Brigham agreement and the planned introduction of a lower-cost, patented NR salt form aimed at reducing cost of goods sold in 2027.